XTX Ventures has backed Cambridge University spin-out Lucida Medical, which raised seed funding from a group of investors including the Prostate Cancer Research charity.
The capital will aid Lucida Medical in developing its AI technology that more accurately analyses MRI in diagnosing prostate cancer. The investment was in the millions of pounds and is a major advance for the company in its goal of saving time for radiologists and allowing patients to receive the best possible diagnosis and treatment.
The funding from XTX Ventures will be used to extend the team, achieve appropriate . . .
Continue Reading
Unlock this article instantly, along with the rest of our premium content and benefits including daily/weekly/monthly newsletters.
Monthly
$30
A pay-as-you-go plan to get you started
→ Instantly unlock all new and archived articles
→ Daily, weekly and monthly e-mail newsletters
→ Access to the weekly AW Deal Watch by AW Research
Annual
$300
Required for access to AW Research
Get more for less - 20% discount over monthly
→ Everything in Monthly PLUS:
→ Access to articles and data from AW Research
→ AW Annual Investor Compendium – our comprehensive guide to investor activity, with a ranking of the most active investors for the year and profiles of the top global allocators
